,27 Moreover, the selected clinical candidate from this series, ACT1004-1239, was reported to have therapeutic potential in animal models of MS and has entered clinical trials.28, 29, 30 Additionally, a different series of moderately active ACKR3 antagonists for the recruitment of β-arrestin2 was also reported by Pfizer recently.50 The gene discussed is ACKR3; the disease is myeloid sarcoma.